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In patients with carotid disease, the purpose of carotid artery revascularization is stroke prevention. For.50 years, carotid endarterectomy has
been considered the standard treatment for severe asymptomatic and symptomatic carotid stenoses. Carotid artery stenting (CAS) has emerged
in the last 15 years as minimally invasive alternative to surgery. However, the value of the endovascular approach in the management of carotid
disease patients remains highly controversial. The aims of this review are to elucidate the current role of CAS, to describe the major technology
advancements in the field, and to speculate about the future of this therapy.
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Introduction
Ten to 15% of all ischaemic strokes originate from a stenosis at the
level of the internal carotid artery. In patients with carotid disease,
the purpose of carotid revascularization is the prevention of (recur-
rent) stroke. For.50 years carotid endarterectomy (CEA) has been
considered the standard treatment for severe asymptomatic and
symptomatic carotid stenoses. Carotid artery stenting (CAS) has
emerged in the last 15 years as minimally invasive alternative to
surgery.1 However, its role remains highly controversial. The
debate has been fuelled by the multiples medical specialties involved
aswell as by the disappointing results of CAS in randomized compar-
isonswithCEA.While somehave interpreted those findings as clear-
cut clinical evidence, other have suggested that most of the trials may
have compared the two revascularization modalities in an unfair
way.2 Aims of this review are to elucidate the current role of CAS
in the management of patients with advanced carotid disease, to de-
scribe themajor technology advancements in the field, and to specu-
late about the future of this therapy.
Clinical data
Major randomized trials of carotid artery
stenting vs. carotid endarterectomy and
meta-analysis
Six major trials have randomized a total of 6780 patients to CAS
vs. CEA. While the SAPPHIRE (Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy) trial3
included patients, both symptomatic and asymptomatic, at high risk
for surgery, CAVATAS (Carotid and Vertebral Artery Transluminal
Angioplasty Study),4 SPACE (Stent-Protected Percutaneous Angio-
plastyof theCarotidArtery vs. Endarterectomy),5 EVA-3S (Endarter-
ectomy Versus Angioplasty in Patients with Symptomatic Severe
Carotid Stenosis),6 and ICSS (International Carotid Stenting Study)
enrolled symptomatic patients at standard surgical risk.7 Finally,
the Carotid Revascularization Endarterectomy vs. Stenting Trial
(CREST) enrolled both symptomatic and asymptomatic patients at
standard surgical risk.8 The randomized studies were, to different
degrees, burdened by several limitations, the most important being
the limited endovascular expertise requirements for operators
performing CAS.2
The CAVATAS trial, performed in the late 1990s, randomized 504
symptomatic patients at low-to-moderate risk for surgery toCEA or
carotid angioplasty.4 The incidence of death or stroke at 30 days was
10.0% in the endovascular group and 9.9% in the surgical group. The
study was criticized by the interventional community for the low
stenting rate (26%). Accordingly, in the study initially all patients in
the endovascular arm were treated with balloon angioplasty, while
later the implantation of (balloon expandable) stents was allowed.
Embolic protection devices (EPD) were unavailable at the time. At
8 years, no difference in ipsilateral stroke, ipsilateral stroke or transi-
ent ischaemic attack, or any stroke between the two arms was
observed.9 The SAPPHIRE study randomized 334 patients at a high
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risk for surgery to CASwith the systematic use of EPD or CEA.3 The
trial included asymptomatic (71%) and symptomatic (29%) patients.
The primary endpoint, a composite of death, stroke, or myocardial
infarction (MI) within 30 days after the intervention or death or ipsi-
lateral strokebetween31 and1year showeda trend in favourofCAS,
occurring in 12.2% in the CAS group and in 20.1% in the CEA group
(P ¼ 0.053). Patients who underwent CAS had significantly fewer MI
at 30 days compared with those allocated to CEA (1.9 vs. 6.6%, P ¼
0.04). At 3-year follow-up, CAS and CEA were equally effective in
terms of stroke prevention.10
TheSPACEstudy,which included1200participants andwas termi-
nated because of slow enrolment and lack of funding, found no
difference in the incidence of ipsilateral stroke or death at 30 days
between patients allocated to CAS or CEA, with an event rate of
6.8 and 6.3%, respectively.5 Embolic protection devices were used
in a minority of CAS patients. At 2 years, the outcomes of the two
groups were comparable.11 The EVA-3S trial, which included 527
patients, was stopped prematurely because of a significantly
increased event rate among patients allocated to endovascular treat-
ment (death or stroke 9.6% in the CAS arm and 3.9% in the CEA
arm).6 At 6 months, the incidence of any stroke or death was
11.7% in the CAS group and 6.1% in the CEA group (P ¼ 0.02). At
4-year follow-up, the death or stroke rate still favoured CEA,
driven by the 30 day events. However, beyond 30 days, no difference
in adverse outcomes between CAS and CEAwas observed.12
The ICSS study randomized 1713 symptomatic patients toCASor
CEA, and the primary endpoint was the long-term rate of any fatal or
disabling stroke. The authors reported first an interim safety analysis
showing that the 120-day rate of stroke, death, or procedural MI oc-
curred in 8.5% in the CAS group and 5.2% in the CEA group [hazard
ratio (HR) 1.69; 95%confidence intervals (CI) 1.16–2.45; P ¼ 0.006].
The incidence of disabling stroke or death at 120 days did not differ
(4.0% in the CAS group and 3.2% events in the CEA) but there was
an excess of overall strokes in the endovascular arm (HR 1.92, 95%
CI 1.27–2.89; P ¼ 0.002).7 The use of EPD was not mandatory in
this trial. The final results of the study were just published recently
showing that the 5-year risk incidence of fatal or disabling stroke
did not differ between CAS (6.4%) and CEA (6.5%).13 Beyond 30
days after treatment, therewas no difference in the rates of ipsilateral
stroke in the territory of the treated carotid artery (4.7% for CAS vs.
3.4% for CEA, HR 1.29, 95% CI 0.74–2.24). However, overall an
excess of strokes in the CAS arm persisted, with a 5-year cumulative
risk of 15.2 vs. 9.4% in the CEA group (HR 1.71, 95% CI 1.28–2.30;
P, 0.001), although this did not translate into differences in func-
tional disability and quality of life, as assessed by the modified
Rankin scale and EQ-5D questionnaire.
TheCREST trial randomized 2502 symptomatic and asymptomatic
patients toCASwith embolismprotectionorCEA.Theprimary com-
posite endpoint was stroke, MI, or death from any cause during the
periprocedural period or ipsilateral stroke within 4 years after ran-
domization. Over a median follow-up period of 2.5 years, there was
no significant difference in the estimated 4-year rates of the primary
endpoint between CAS and CEA groups (7.2 and 6.8%, respectively;
HR 1.11; 95% CI 0.81–1.51; P ¼ 0.51).8 The 4-year rate of stroke or
death was 6.4% with CAS and 4.7% with CEA (HR 1.50; P ¼ 0.03);
the rates among symptomatic patients were 8.0 and 6.4% (HR 1.37;
P ¼ 0.14), and the rates among asymptomatic patients were 4.5 and
2.7% (HR1.86; P ¼ 0.07), respectively. Periprocedural event rates dif-
fered between the CAS and CEA for stroke (4.1 vs. 2.3%, P ¼ 0.01)
and MI (1.1 vs. 2.3%, P ¼ 0.03). Beyond 30 days, the incidence of ipsi-
lateral strokewith bothCAS andCEAwas low (2.0 and2.4%, respect-
ively; P ¼ 0.85). Importantly, in the second half of the study, the rateof
stroke in the CAS arm, but not in the CEA arm, showed a significant
reduction, suggesting a learning curve effect in the endovascular
arm.14 Finally, in CREST, there was an association between the pres-
ence of periprocedural MI, more common in the CEA arm, and long-
termmortality.Thiswasnot thecase for theendpointofminor stroke,
which was as mentioned more common in the CAS arm.14
A meta-analysis of randomized controlled trials including 3754
patient treated with CAS and 3723 patients undergoing CEA
showed that at 30 days, CAS was associated with an significantly
elevated risk of stroke [Odds Ratio (OR) 1.53, 95% CI 1.23–1.91;
P, 0.001], death or stroke (OR 1.54, 95% CI 1.25–1.89; P,
0.001) while MI (OR 0.48, 95% CI 0.29–0.78; P ¼ 0.003) and
cranial nerve injuries (OR 0.09, 95% CI 0.05, 0.16; P, 0.001) were
significantly reduced compared with CEA.15 Beyond 30 days, the
efficacy of the two revascularization strategies in terms of ipsilateral
stroke prevention and their safety in terms of restenosis and need for
repeat revascularization was comparable in all trials.
Ongoing randomized carotid
revascularization trials
The randomized, controlled, open, multi-centre three-armed
SPACE-2 study started in 2009 aiming to compare state-of-the-art
medical prevention including lifestyle modification with CEA and
CAS in patients with severe asymptomatic carotid stenosis. Due to
low recruitment, the steering committee decided in 2012 to
modify the protocol and to split this three-arm trial into two separate
two-arm clinical trials [CEA + best medical treatment vs. best
medical treatment alone (SPACE-2A) andCAS + bestmedical treat-
ment vs. best medical treatment alone (SPACE-2B)].16 The Asymp-
tomatic Carotid Surgery Trial-2 (ACST-2) is enrolling up to 5000
patients with severe asymptomatic carotid stenosis randomly allo-
cated to CEA or CAS. In an interim safety analysis of the first 691
patients enrolled, the investigators reported a disabling stroke, fatal
MI, and death rate of 1.0%.17
TheCarotid Stenting vs. Surgeryof SevereCarotidArteryDisease
and Stroke Prevention in Asymptomatic Patients (ACTI) trial rando-
mized asymptomatic patients to CAS vs. CEA in a 3 : 1 ratio. The
study has been prematurely halted after the enrolment of 1600
patients and the results have not been presented yet. The carotid
revascularization for primary prevention of stroke (CREST-2)
study is composed of two independent multi-centre, randomized
controlled trials of carotid revascularization and best medical man-
agement vs. medical management alone in patients with asymptom-
atic high-grade carotid stenosis. One trial will randomize patients in
a 1 : 1 ratio to CEA vs. no CEA and another will allocate patients in
a 1 : 1 ratio to CAS vs. no CAS. Medical management will be
uniform for all groups. The study plans to include 2480 patients and
enrolment is supposed to start at the end of 2014.
In summary, no trial is planned to address the most relevant issue,
namely the comparative value of CAS and CEA in symptomatic
patients. For asymptomatic patients some, but likely non-conclusive
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Table 1 30-day event rates in carotid artery stenting registries enrolling over 1000 patients
Name Year Country N Industry
sponsored
Surgical
high risk
EPD Sympt
patients (%)
Neuroa CEC adjud. D/S D/S/MI D/S sympt D/S asymp
CAPTURE31 2007 USA 3500 Yes Yes Mandatory 14 Yes Yes 5.7% 6.3% 10.6% 4.9%
CASES PMS32 2007 USA 1493 Yes Yes Mandatory 22 Yes Yes 4.5% 5.0% NR NR
PRO-CAS33 2008 D 5341 No No 75% 55 70% No 3.6%b NR 4.3%b 2.7%b
SAPPHIRE-W34 2009 USA
+
2001 Yes Yes Mandatory 28 Noc Yes 4.0% 4.4% NR NR
SVS35 2009 USA 1450 No Yes 95% 45 No No NR 5.7% NR NR
EXACT36 2009 USA 2145 Yes Yes Mandatory 10 Yes Yes 4.1% NR 7.0% 3.7%
CAPTURE-236 2009 USA 4175 Yes Yes Mandatory 13 Yes Yes 3.4% NR 6.2% 3.0%
Mercoglianob,f,37 2010 I 1300 No No Mandatoryd 28 No No 1.4% 1.4% 3.0% 0.8%
Krakowb,f,38 2012 P 1081 No No Mandatory 51 No No NR 2.6% 3.6% 1.5%
CABANA39 2014 USA 1025e Yes Yes Mandatory 32 Yes Yes 4.1% 4.6% NR NR
EPD, emboli protection devices; sympt, symptomatic; asympt, asymptomatic; CEC adjud., clinical event committee adjudication; D, death; S, stroke; MI, myocardial infraction; NR, not reported; D, Deutchsland 7 (country); I, Italy; P, Poland.
+ USA and Canada.
aNeuro, independent pre- and post-procedural assessment by a neurologist.
bIn-hospital events.
cNeurologic assessment performed by stroke scale certified staff member.
dMo.Ma proximal protection.
e1097 patients enrolled and 1025 patients evaluable for 30-day events.
fSingle-centre study.
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data should be soon available from the ACT-I trial, while from the
most important trial, namely ACST-2, no data will be available for
several years to come. Finally, both SPACE-2 and CREST-2, if com-
pleted, will allow due to their design only indirect comparisons
between CAS and CEA.
Large-scale registries
The results of 10 CAS large-scale registries (i.e. enrolling over 1000
patients) have been published, for a total of 23 511 patients treated
(Table 1). The use of EPD was mandatory in the majority of the
studies. The highest quality studies came from the Unites States,
withmost of the registries beingmandated by the FDA and having in-
dependentneurologic assessmentpre- andpost-procedureaswell as
clinical event committee adjudicationof adverseoutcomes.Themain
limitation of the registries is that the proportion of symptomatic
patients was modest. Overall, the outcomes can be considered fa-
vourable, with a 30-day death, stroke, or MI rate ranging from 1.4
to 6.3%, especially if considered that several registries included
only patients at high surgical risk and that the event rates have
decreased over the years.
Technology advancements
Although the insufficient expertise, both in terms of skills and in
patient selection, may be the main factor leading to stroke excess
in CAS compared with CEA, CAS as it was performed in the rando-
mized trials carried some intrinsic limitations:
(i) distal EPD (filters) may not adequately protect the brain in all
settings, due to incomplete apposition to the vessel wall, lack
of protection during placement of the EPD, and the passage of
micro-emboli smaller that the pore size of the filter;
(ii) current stent frames may have insufficient lesion scaffolding
properties and allow for intra-strut plaque prolapse;
(iii) catheter manipulations at the level of the aortic arch may be an
important source of emboli not prevented by current EPD
technology.
Some of those limitations have been addressed by recent technology
advancements described below.
Proximal cerebral protection
Proximal EPD protects the brain by interrupting or reversing the
bloodflowat the levelof thecarotidbifurcationat the timeof thepro-
cedure. This approach as emerged as alternative to distal EPD
(filters). The main advantages of proximal protection include cross-
ing of the lesion under protected conditions aswell as the blockageof
both macro- and micro-emboli. Finally, with proximal protection
there is no placement of a device in the distal internal carotid
artery, and this may reduce the risk of arterial spasm, dissection, or
intimal damage. Drawbacks of this technique include the larger
sheath size required, which may be problematic in patients with
advanced peripheral arterial disease and may be associated with an
increased rate of vascular access complications, as well as the inter-
ruption of brain perfusion leading to an intolerance with transient
neurologic symptoms in 3–8%of the patients.18 Proximal protection
should not be used in patients with advanced external or common
carotid disease and its applicability in patients with contralateral
carotid occlusion depend on the extent of the collateralization
through the Circle of Willis. Finally, the procedure is somehow less
Figure1 Mo.Ma
TM
working concept and device. The distal and the proximal balloons occlude the external carotid artery and the common carotid
artery (left panel). The contemporary inflation of both balloons prevents flow in the internal carotid artery coming antegradely from the common
carotid artery and retrogradely from the external carotid artery. Through the working channel the carotid lesion can be crossed and treated under
flow blockage, preventing cerebral embolization. The device is illustrated in the right panel.
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straightforward than filter-protected CAS and requires additional
skills. Two proximal protection EPD systems are available.
Mo.Ma
TM
(Medtronic-Invatec, Roncadelle, Italy)
The Mo.Ma system consists of an 8F or 9F sheath with an effective
working channel of a 5F and 6F sheaths, respectively, and two inde-
pendently inflatable balloon catheters (Figure 1). The distal balloon
is located close to the sheath tips and occludes the external carotid
artery. The proximal balloon is positioned in the common carotid
artery. When inflated, both balloons prevent flow in the internal
carotid artery coming both antegradely from the common carotid
artery and retrogradely from the external carotid artery. As a
result, the carotid lesion can be crossed and treated under flow
blockage, preventing cerebral embolization. After the lesion is
treated, three 20 mL syringes of carotid blood are aspirated and
checked for debris before deflating the distal and then the proximal
balloons, reestablishing cerebral blood flow.
NeuroProtection System
TM
(WL Gore and Associates,
Flagstaff, AZ, USA)
The NeuroProtection System is a distal EPD that promotes passive
reverse flow in the internal carotid artery. It is composed of two in-
dependent systems: the balloon wire and the 9F sheath which has an
effective working channel of a 6F sheath and contains an inflatable
balloon at its tip (Figure 2). The sheath is positioned in the common
carotid artery and the balloon wire is inserted through the sheath
and positioned at the external carotid artery. When both balloons
are inflated, the blood flow through the common and external caro-
tids is blocked. The proximal part of the sheath is connected to the
contralateral femoral vein, allowing blood flow reversal of blood
from the cerebral circulation (i.e. the Circle of Willis) down the in-
ternal carotid artery and through the sheath into the venous
system. The blood flows through a filter with a pore size of
180 mm which collects debris before the blood re-enters the circu-
lation through the femoral vein. As a consequence, the carotid
lesion can be crossed and treated in reverse-flow mode. At the
end of the procedure, 10–20 mL of carotid blood are actively
aspirated and then the balloons are deflated while active suction is
applied to retrieve any particle contiguous to the balloon occluder.
Clinical data on proximal protected carotid artery stenting
The available clinical experience consisted of five multi-centre regis-
tries and one large-scale single-centre registry and has been summar-
ized in a meta-analysis.18 Among 2397 patients, 31% of them being
symptomatic, the 30-day rate of composite stroke, MI, or death
was 2.25%. Stroke, MI, and death were encountered in 1.71, 0.02,
and 0.40%, respectively. Age and diabetic status were found to be
the only significant independent risk predictors and stroke rates
below2.6%were found in all subgroups, including symptomatic octo-
genarians. In this analysis, gender, symptomatic status and contralat-
eral carotid occlusion were not associated with adverse events.
ENROUTE
TM
neuroprotection system (formerly
MICHI
TM
neuroprotection system, Silk Road Medical,
Sunnyvale, CA, US)
The ENROUTE
TM
system is a flow reversal circuit consisting of two
sheaths, one placed below in the common carotid via a transcervical
approach connected to a transfemoral venous line (Figure 3).
Figure 2 NeuroProtection System
TM
working concept (A) and device (B) with its multiple ports (arrows).
Figure 3 Schematic diagram of the component parts and layout
of the ENROUTE
TM
system.
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The arterial sheath is placed via a surgical incisionof around2 cm in
length above the clavicle on the side to be treated while the venous
sheath is inserted into the femoral vein and an arterio-venous shunt is
created.When the carotid artery is occluded just proximal to the ar-
terial sheath, the resulting pressure gradient induces flow reversal.
No blockage of flow in the ipsilateral external carotid is necessary.
Themain advantage of this approach is the lack of cathetermanipula-
tions at the level of the aortic arch. Downsides include the need for a
surgical incision as well as for a disease-free portion of common
carotid artery at the site of cut-down. Finally, the working length
between the access point in the common carotid and the carotid
bifurcation needs to be at least five cm.
Clinical data on ENROUTE
TM
system protected carotid
artery stenting
At this stage, the ENROUTE
TM
system has undergone only limited
clinical evaluation and should be considered an experimental
device. In a first-in-man single-arm feasibility study including 44
patients, no major stroke, MI, death, or cranial nerve injury was
reported. At 30 days, one minor contralateral stroke occurred in a
patient who was free of lesions on post-procedural DWMRI.19
A total of 31 patients underwent pre- and post-procedure DWMRI
investigations. Five patients (16.1%) had new lesions on the post-
procedural scan, representing the lowest DWMRI rate of any
carotid stenting strategy reported to date.
Double layer mesh stent technology
While in coronary interventions miniaturization and refinement of
stent design has allowed the interventionalists to perform more
complex procedures and to solve most of the limitations of stenting,
inCAS little research anddevelopment efforts havebeen allocated to
improve stent characteristics. Recently, it has been recognized that
the stent itself may substantially add to embolic protection in CAS
through adequate scaffolding of the plaque once the EPD has been
removed. The ideal properties of a carotid stent are a well-balanced
mix of high flexibility and conformability, to accommodate tortuous
anatomy, as well as high plaque coverage, to prevent late emboliza-
tion of debris. Stents structure is characterized by sequential
aligned annular rings interconnected by bridges and the design may
be either open cell or closed cell, depending on the density of the
bridges between the rings.
Figure4 Optical coherence tomographyfindings inside anopen-cell carotid stent. (A)Malappositionof the stent to the vesselwhile (B) intra-strut
plaque prolapse (arrows).
Figure 5 The self-expanding double layer mesh carotid stent
RoadSaver
TM
(Terumo, Japan).
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Open-cell design stents present some of the segments free from
the adjacent rings allowing greater adaptation to the vessel
anatomy at the price of less plaque coverage and higher risk of
tissue prolapse. Closed-cell design stents are characterized by
higher density of bridge interconnection, which reduces their con-
formability and increases the probability of malapposition but at
the same time offers greater plaque coverage. A hybrid configuration
with an open-cell design of the proximal and distal segments com-
bined with a closed-cell design of the central segments has been re-
cently developed. The impact of stent design on clinical outcome
following CAS has not been adequately addressed. An observational
study found a significant lower rate of post-procedural events in
Figure6 Optimal coherence tomography assessment of a RoadSaver
TM
stent showing no significant prolapse of plaque and goodwall apposition.
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patients undergoing closed-cell design stent implantation compared
with individual allocated to open-cell design stenting, but these
results were not confirmed by other registries showing poor
correlation between in-hospital and 30 days mortality and stent
design.20–23
A nice insight in the impact of stent design and in the pathophysi-
ology at the lesion level at the time of CAS comes from a prospective
single-centre study enrolling 40 consecutive patients and designed to
evaluate the rateof stentmalapposition, plaqueprolapse, and thin cap
fibro-atheroma rupture according to stent configuration by optical
coherence tomography (OCT) (Figure 4).24 Closed-cell design
stents were used in 17 patients (42.5%), open-cell design stents in
13 patients (32.5%), and hybrid design stents in 10 patients (25%).
No neurological complications occurred. On OCT analysis, the fre-
quencies of malapposed struts were higher with closed-call com-
pared with open-cell and hybrid design stents (34.5 vs. 15% and
16.3%, respectively; P, 0.01). Plaque prolapse was more frequent
with open cell than closed cell (68.6 vs. 23.3%; P, 0.01) and
hybrid stents (30.8%; P, 0.01). Significant differences were also
noted in the rates of fibrous cap rupture between closed- and
open cell (24.2 vs. 43.8%; P, 0.01), and between closed-cell and
hybrid design (39.6%; P, 0.01) stents, but not between open-cell
and hybrid design stents (P ¼ 0.4). The authors concluded that
micro-defects after stent deployment in CAS are frequent and are
related to the design of implanted stents. While stent malapposition
was more common following closed-cell design stent implantation,
plaque prolapse was more common in patients treated with open-
cell design devices. While these results are important, a correlation
to clinical events remains to be demonstrated.
Themechanismof delayed cerebral embolization followingCAS is
unknown but may include tissue prolapsed through the stent struts
and thrombus formation around malapposed stent struts. Despite
the fact that currentguidelines recommendcarotidartery revascular-
ization exclusively on the basis of stenosis severity, the importance of
plaque characterization in stratifying stroke risk has been increasingly
recognized. The weak correlation between the severity of stenosis
and the risk of stroke in asymptomatic patients found in several
trials together with recently published data that link complex
plaques with stroke challenge the ‘degree of stenosis-stroke risk’
paradigm, highlight the importance of the morphology and compos-
ition of the carotid plaques beyond the degree of stenosis and of the
investigationof the complex stent–plaque interaction afterCAS.24,25
In this respect, calcified lesionsmay favour stent malapposition while
soft plaques may result in greater tissue prolapse though the stent
struts.
Recently, a novel carotid stent design has been developed, namely
the double layermesh stent. The design should allow for high flexibil-
ity to accommodate tortuous anatomy and at the same time convey
scaffold properties for optimal plaque coverage. This technology is
characterized by an internal micromesh layer for plaque coverage
and an external self-expanding nitinol layer for scaffolding offering
the flexibility that characterize open-cell design stents. Currently,
the only CE marked and commercially available double layer mesh
stent is illustrated in Figure 6. The device is compatible with a
0.014′′ guide wire and 7F guiding catheter or 6F long sheath. The
cell size of the micromesh is extremely small (0.381 mm2) allowing
for extensive plaque coverage (Figures 5 and 6). It remains to be
demonstrated whether this interesting concept will translate into a
reduction of neurologic events associated with CAS.
Transradial approach
The transradial approach may be a valuable alternative to transfe-
moral access for CAS in patients with advanced peripheral vascular
disease of with complex aortic arches such as the bovine or the
type III arches.26 Transradial access for CAS was first reported in
1999, and several case reports and few small case series followed.27
The largest series so far published included 382 patients treated in
two high-volume centres and documented an overall success rate
of 91% and a stroke rate of 1.3%.28 Recently, a randomized single-
centre trial allocating 260 consecutive patients at high risk for CEA
to transradial or transfemoral CAS reported excellent outcomes
with both strategies with an incidence of procedural major adverse
cardiac and cerebral events,1.0% in both groups. Froma transradial
route, technical success was achieved in 90% of cases while 10% of
patients requiredacrossover to a trasnfemoral access.Major vascular
complications were rare (,1% in both groups).29
Future directions
Carotid stenting, although it is a mature technique regularly applied
with excellent outcomes in high-volume centres by expert opera-
tors, is struggling to find the consensus of the scientific community.
The initial enthusiasm for CAS as a valuable and less invasive alterna-
tive to CEA has been mitigated by the undisputable gap in outcomes
between the two strategies observed in randomized clinical trials. In-
adequate requirements in terms of endovascular expertise, poten-
tially leading to an increased event rate related to both insufficient
technical skills and inadequate patient selection, has been proposed
as the main reason for the unfavourable outcomes related to CAS.
Despite the fact that high-quality multi-centre registries and high-
volume single-centre experiences have consistently described fa-
vourable CAS outcomes, the evidence has not been considered
sufficient in the neurologist community to recommend CAS. In add-
ition, in somecountries including theUnitedStates theprocedurehas
been reimbursed only within research protocols. Overall, the num-
ber of procedures performed in recent years is stagnant if not
decreasing and industry massively reduced funding for research, de-
velopment, and clinical trials. Unfortunately, in the next years little
additional randomized data comparing CAS and CEA are to be
expected. The promising technologies describedmay reverse the cur-
rently unfavourable trend for CAS only if they will be given the chance
to be tested in adequately powered clinical trials, which require major
funding by either industry or private or public entities.30
Conflict of interest: S.M. is a Chief Medical Officer, Silk Road
Medical.
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